These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33573814)

  • 1. Presentation and Outcomes of Antibody-Mediated Rejection Associated With Angiotensin II Receptor 1 Antibodies Among Kidney Transplant Recipients.
    Abuzeineh M; Kyeso Y; Philogene MC; Alachkar N; Alasfar S
    Transplant Proc; 2021 Jun; 53(5):1501-1508. PubMed ID: 33573814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients.
    Lefaucheur C; Viglietti D; Bouatou Y; Philippe A; Pievani D; Aubert O; Duong Van Huyen JP; Taupin JL; Glotz D; Legendre C; Loupy A; Halloran PF; Dragun D
    Kidney Int; 2019 Jul; 96(1):189-201. PubMed ID: 31005275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients.
    Fichtner A; Süsal C; Schröder C; Höcker B; Rieger S; Waldherr R; Westhoff JH; Sander A; Dragun D; Tönshoff B
    Nephrol Dial Transplant; 2018 Jun; 33(6):1065-1072. PubMed ID: 29444269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies.
    Fuss A; Hope CM; Deayton S; Bennett GD; Holdsworth R; Carroll RP; Coates PT
    Nephrology (Carlton); 2015 Jul; 20(7):467-73. PubMed ID: 25726938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Zmonarski S; Protasiewicz M; Nowakowska B; Hałoń A; Chudoba P; Klinger M
    Transpl Int; 2014 Oct; 27(10):1029-38. PubMed ID: 24909812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of angiotensin II type 1 receptor antibodies on graft function and survival in paediatric kidney transplant recipients.
    Kermond RF; Kim S; Mackie F; Hahn D; Carroll RP; Sharma A; Durkan AM
    HLA; 2024 Sep; 104(3):e15649. PubMed ID: 39247998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II receptor 1 antibodies associate with post-transplant focal segmental glomerulosclerosis and proteinuria.
    Abuzeineh M; Aala A; Alasfar S; Alachkar N
    BMC Nephrol; 2020 Jul; 21(1):253. PubMed ID: 32615995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kidney re-transplantation in a child across the barrier of persisting angiotensin II type I receptor antibodies.
    Gold A; Fichtner A; Choukair D; Schmitt CP; Süsal C; Dragun D; Tönshoff B
    Pediatr Nephrol; 2021 Mar; 36(3):725-729. PubMed ID: 33355703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathologic changes in anti-angiotensin II type 1 receptor antibody-positive kidney transplant recipients with acute rejection and no donor specific HLA antibodies.
    Lim MA; Palmer M; Trofe-Clark J; Bloom RD; Jackson A; Philogene MC; Kamoun M
    Hum Immunol; 2017 Apr; 78(4):350-356. PubMed ID: 28284829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of therapeutic plasma exchange on angiotensin II type-1 receptor antibodies on two kidney transplant recipients.
    Yamada C; Huang Y; Norman S; Naik A; Moussa O; Samaniego M; Cooling L
    J Clin Apher; 2018 Dec; 33(6):673-677. PubMed ID: 30321467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Antibodies Directed Against Two GPCRs, Anti-AT1R and Anti-ETAR, on Kidney Transplant Outcome.
    El Band JEK; Llorente S; Martinez-Garcia P; Alfaro R; Jimenez-Coll V; Boix F; Galián JA; Martinez-Banaclocha H; Botella C; Moya-Quiles MR; Minguela A; Legaz I; Muro M
    Curr Protein Pept Sci; 2021; 22(10):745-757. PubMed ID: 34967284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is pre-transplant sensitization against angiotensin II type 1 receptor still a risk factor of graft and patient outcome in kidney transplantation in the anti-HLA Luminex era? A retrospective study.
    Deltombe C; Gillaizeau F; Anglicheau D; Morelon E; Trébern-Launay K; Le Borgne F; Rimbert M; Guérif P; Malard-Castagnet S; Foucher Y; Giral M
    Transpl Int; 2017 Nov; 30(11):1150-1160. PubMed ID: 28686316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rejection and graft outcomes in kidney transplant recipients with and without angiotensin II receptor type 1 antibodies.
    Aljishi M; Isbel NM; Jegatheesan D; Johnson DW; Cho Y; Campbell SB; Hawley CM; Thornton A; Gillis D; Johnstone K
    Transpl Immunol; 2023 Feb; 76():101756. PubMed ID: 36460263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deleterious effect of anti-angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor-specific anti-HLA antibodies.
    Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Nephrology (Carlton); 2019 Mar; 24(3):347-356. PubMed ID: 29451342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies.
    Philogene MC; Bagnasco S; Kraus ES; Montgomery RA; Dragun D; Leffell MS; Zachary AA; Jackson AM
    Transplantation; 2017 Mar; 101(3):608-615. PubMed ID: 27222934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-transplant AT1R antibodies and long-term outcomes in kidney transplant recipients with a functioning graft for more than 5 years.
    Aziz F; Jung-Hynes B; Parajuli S; Redfield RR; Astor BC; Mandelbrot D; Hidalgo L; Djamali A
    Clin Nephrol; 2020 Nov; 94(5):245-251. PubMed ID: 32870149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of angiotensin II type 1 receptor antibodies in antibody-mediated rejection without detectable donor-specific HLA antibodies after renal transplantation.
    Lee J; Park Y; Kim BS; Lee JG; Kim HJ; Kim YS; Huh KH
    Transplant Proc; 2015 Apr; 47(3):649-52. PubMed ID: 25891704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome.
    Reinsmoen NL; Lai CH; Mirocha J; Cao K; Ong G; Naim M; Wang Q; Haas M; Rafiei M; Czer L; Patel J; Kobashigawa J
    Transplantation; 2014 Mar; 97(5):595-601. PubMed ID: 24162250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-transplant Screening for Non-HLA Antibodies: Who should be Tested?
    Philogene MC; Zhou S; Lonze BE; Bagnasco S; Alasfar S; Montgomery RA; Kraus E; Jackson AM; Leffell MS; Zachary AA
    Hum Immunol; 2018 Apr; 79(4):195-202. PubMed ID: 29428484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of anti-angiotensin II type 1 receptor antibodies on the outcomes of kidney transplantation: a systematic review and meta-analysis.
    Kang ZY; Liu C; Liu W; Li DH
    Nephrol Dial Transplant; 2022 May; 37(6):1171-1180. PubMed ID: 34865146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.